Reason for request
New indication
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of LIBTAYO (cemiplimab) in association with a platinum salt-based chemotherapy regimen, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
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
h7HHVmdydagM9Fk4
